Regina Barragan-Carrillo, MD, discusses results of a study which sought to assess the association between thymectomy and incidence of renal cell carcinoma.
Regina Barragan-Carrillo, MD, medical oncologist, postdoctoral fellow, Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, discusses results of a study which sought to assess the association between thymectomy and incidence of renal cell carcinoma (RCC).
Transcription:
0:09 | For the end points that we tested for the rate of nephrectomies, or renal serve diagnosis specifically, how we did this and how we chose that is because of the methodology we had available. We used the [California Office of Statewide Health Planning and Development (OSHPD)] database, which is the standard for the office of statewide planning and development which is a database based in California, which accounts for all the procedures that are done in the in an outpatient setting, and also for [emergency room] visits. What we have seen with the information available are the procedures through the CPT and ICD-9/10 coding.
0:49 | What we decided is to use the coding for thymectomy and the coding for nephrectomy to identify both groups. For example, the rate we have in the state of California accounting for all adult patients, meaning 40 years or older, the rate we have for nephrectomy for renal cell carcinoma is around 0.2%. The rate we noticed in those patients who have previously undergone a thymectomy was 0.56%, which is more than double than we would have expected for the state of California.
1:26 | One might raise the question, and I think it is a valid question, whether there was a risk of bias in the selection of the population because these are patients who are already under certain scrutiny because of their past surgical history, so we included in our analysis, another 3 surgical procedures, which were a cholecystectomy, a hip arthroscopy, and a knee arthroscopy, and in all of 3 subpopulations who had undergone those procedures and afterwards required nephrectomy for RCC, the rates for RCC re diagnosis were also pretty similar to what we saw in the overall population, which were around 0.20%. Historically, the numbers make sense in that regard, and the difference between the patients with a prior thymectomy was quite clear to us.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More